Multiple Sclerosis Treatment: World Drug Market 2012-2022
NEW YORK, Dec. 27, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Multiple Sclerosis Treatment: World Drug Market 2012-2022http://www.reportlinker.com/p0739372/Multiple-Sclerosis-Treatment-World-Drug-Market-2012-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
What are the commercial prospects for multiple sclerosis treatment? Visiongain's report shows you potential drug revenues to 2022. Find data, forecasts and discussions.
Discover revenue predictions for multiple sclerosis (MS) treatments at world market, product and national levels to 2022. Our report gives you business research, analysis and data.
How will the drugs Copaxone, Avonex, Rebif, Betaseron/Betaferon, Tysabri, Extavia and Gilenya perform to 2022? You can find potential revenues. Discover information on disease-modifying agents for MS, the main focus of this work.
This study discusses Biogen Idec, Teva, Sanofi, Novartis, Merck Serono, Bayer and other pharmaceutical companies. Receive information you need.
What does the future hold? With a strong R&D pipeline, the MS treatment sector has potential to expand.
The market will change with the launch of new agents that slow symptom progression and reduce relapse rates. Find R&D trends and commercial opportunities there.
Visiongain's report provides data, analysis and opinion aiming to benefit your research, calculations, meetings and presentations. You can find answers now in our work.
Revenue forecasts, market shares, developmental trends, discussions and interviews Advantages of Multiple Sclerosis Treatment: World Drug Market 2012-2022 for your work• Find potential revenue to 2022 for the world MS drug market, viewing sales growth
• Discover revenue forecasts to 2022 for leading MS drugs, assessing commercial potential
• Assess leading companies, discovering their activities and prospects
• See revenue forecasts to 2022 for leading national markets - US, Japan, UK,Germany, France, Spain, Italy, China and India
• Review R&D for treating MS, seeing pipeline trends
• Investigate competition and opportunities influencing the industry and its sales
• Find out what will stimulate and restrain the industry and market
• View opinions from our survey, discovering research interviews.
There, you find a distinctive mix of quantitative and qualitative analyses with independent predictions. We tackle crucial questions on MS treatment, helping you to stay ahead.
Gain business research, data and analysis for multiple sclerosis drug treatments
Our report is for everybody needing industry and market analysis for drug-based MS treatment. Find data, trends and answers. Avoid missing out - please order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Table of Contents1.1 Multiple Sclerosis: Treatment Market Overview
1.2 Chapter Breakdown
1.3 Research and Analysis Methods
2. Introduction to Multiple Sclerosis and its Treatment2.1 The Pathology of Multiple Sclerosis2.2 Diagnosis of MS2.3 Measuring MS2.4 The Different Types of Multiple Sclerosis2.4.1 Relapsing Remitting MS2.4.2 Secondary Progressive MS2.4.3 Progressive Relapsing MS2.4.4 Primary Progressive MS2.4.5 Other Presentations of the Disease2.5 Possible Causational Factors for MS2.5.1 Genetic Factors2.5.2 Infection2.5.3 Environmental Factors and Less Well-Supported Theories2.6 Demographics and Geographical Distribution2.7 Economic Costs2.8 Treatment Options2.8.1 Treatment of Symptoms2.8.2 Treatment of Attacks2.8.3 Treatment of Disease Progression (Disease-Modifying Treatments)2.8.4 Other Drugs and Off-Label Treatments2.8.4.1 Rituxan (Rituximab, MabThera)2.8.4.2 Campath (Alemtuzumab)2.8.4.3 Novantrone (Mitoxantrone)2.8.4.4 Imuran (Azothioprene)2.8.4.5 Cyclophosphamide2.8.4.6 Intravenous Immunoglobulin (IVIg)2.8.4.7 Methotrexate (Maxtrex)2.8.4.8 Low-Dose Naltrexone2.8.5 Alternative Treatments
3. The World Market for MS Drugs, 2011-2022
3.1 The MS Market in 2010
3.2 Copaxone Led the MS Drug Market in 2010
3.3 Together, Interferons Form Over Half the Market
3.4 Market Forecast, 2010-2022
3.4.1 The Impact of New Drugs on the MS Market
3.4.2 The Impact of Generic Drugs on the MS Market
4. Leading National Markets for MS Drugs, 2011-20224.1 MS Drug Sales and Market Shares in Leading National Markets, 20104.2 Leading MS Markets: Sales Forecasts, 2011-20224.3 The US Is the Largest Market for MS Drugs4.4 Europe4.4.1 Germany Has the Largest EU Market for MS Drugs4.4.2 France4.4.3 Spain4.4.4 Italy4.4.5 The UK4.5 Japan4.6 India4.7 China
5. Drugs for Treating MS: Sales Prospects, 2011-2022
5.1 Copaxone
5.1.1 Copaxone Sales Forecast 2011-2022
5.1.2 Copaxone Will Benefit from Label Extension
5.2 Threat from Generic Competition for Copaxone
5.3 Avonex
5.3.1 Method of Use Patent Extension to 2026
5.3.2 PEG-Avonex
5.4 Rebif
5.5 Betaseron/Betaferon
5.6 Tysabri
5.6.1 PML and the JCV Assay
5.7 Extavia
5.8 Gilenya
5.8.1 Quarter-on-Quarter Growth of Gilenya
5.9 Biosimilars
6. Leading Companies in the MS Drug Industry6.1 Biogen Idec6.1.1 Biogen Idec's Strong MS Pipeline6.1.2 Biogen Has Licensed Ampyra, a Novel Treatment for MS Symptoms6.1.3 The Threat of Biosimilars6.2 Teva and Sanofi6.2.1 Threats to Copaxone6.2.1.1 Generic Competition for Copaxone6.2.1.2 BG-126.2.1.3 Pipeline Copolymers6.2.2 Opportunities for Copaxone6.2.3 Extending Teva's MS Drug Franchise6.3 Novartis6.4 Merck Serono6.5 Bayer
7. The R&D Pipeline for Disease-Modifying MS Treatment
7.1 MS Pipeline Drugs
7.2 Fast Forward
7.3 Modifications of Existing Drugs
7.3.1 PEG-INF (PEGylated Interferon Beta-1a)
7.3.2 NU100 (Interferon beta-1b) and NU400 (PEGylated Interferon Beta-1b)
7.3.3 Adjunct Therapies
7.4 Drugs that Regulate the Immune Response
7.4.1 Aubagio (Teriflunomide)
7.4.2 Laquinimod
7.4.3 Zanapax (Daclizumab)
7.4.4 Lemtrada/Campath (Alemtuzumab)
7.4.5 Oreclizumab
7.4.6 Trimesta
7.4.7 PI-2301
7.5 Anti-Inflammatory Drugs
7.5.1 BG-12 (Dimethyl Fumarate)
7.6 Drugs that Promote Remyelination
7.6.1 Olexisome
7.7 Vaccine Therapies
7.7.1 Tovaxin
7.7.2 BHT-3009
7.8 Stem Cell Treatment
7.9 Sativex
7.10 There is Strong Potential in the MS Drug Pipeline
8. Factors that Influence the MS Drug Industry and Market8.1 SWOT Analysis8.2 Market Drivers8.2.1 The MS Market Has Opportunities for Continuing Growth8.2.2 Labelling Extensions for New Indications Can Drive Uptake8.2.3 Competition Between Older and Newer Products8.2.4 Other Services8.2.5 Drug Preference8.2.6 Advances in Technology Will Benefit Patients and the Market8.2.6.1 Targeting Patient Subpopulations8.2.7 The Rise of Comparative Studies8.3 Market Restraints8.3.1 The Threat of Generics and Biosimilars (Follow-on Biologics)8.3.2 Cost Concerns8.3.3 Off-Label Use and Risk-Sharing Schemes8.3.4 Side Effects and Treatment Compliance
9. Research Interviews
9.1 Interview with Dr Karen M. Stockl (Prescription Solutions)
9.1.1 Improving Self-Management of MS
9.1.2 The Impact and Benefits of DTM Programmes
9.1.3 Improving Medication Adherence in MS Patients
9.1.4 Impact of Oral MS Medications
9.2 Interview with Dr Johan Luthman (Merck Serono)
9.2.1 On Understanding the Disease and its Treatments
9.2.2 On Unmet Needs for Treatment
9.2.3 On Current Treatment Options
9.2.4 On Medical Marijuana Use
9.2.5 On Oral Drugs
9.2.6 On Future Treatment Possibilities
9.3 Second Interview with Dr Johan Luthman (Merck Serono), Specifically Concerning Stem Cell Potential
9.3.1 On Stem Cell Media Coverage
9.3.2 On the Therapeutic and Curative Potential of Stem Cells for Neurological Disorders
9.3.3 On the Treatment of Neurological Disorders
9.3.4 On Stem Cell Treatment of MS: Viability, Curative Power, Treatment Strategy and Results
9.3.5 On the Time Frame for Marketable Stem Cell Treatment Options
10. Conclusions from the Study10.1 Growth of the MS Market Will Continue, But Will Be Limited by Competition10.2 There Will Be Continued Growth in Leading Markets, Owing to New Products and Expanding Treatment Populations10.3 There is a Strong R&D Pipeline for MS Treatment10.4 Leading Companies in the MS Drug Market10.5 Market Drivers10.6 Market Restraints10.7 Prospects for the MS Drug Market - Concluding Thoughts
List of Tables
Table 2.1 The Kurtzke Expanded Disability Scales (EDSS)Table 2.2 Multiple Sclerosis Populations and Prevalence for Leading Countries, 2011Table 2.3 Licensed Disease Modifying Drugs for Multiple Sclerosis, 2011Table 3.1 Disease-Modifying Drug Sales, 2010Table 3.2 Sales of MS Drugs by Type, 2010Table 3.3 MS Drug Forecasts, 2010-2015Table 3.4 MS Drug Forecasts, 2016-2022Table 3.5 Current Leading Multiple Sclerosis Drugs: Forecast Revenues, 2022Table 4.1 Leading MS Markets by Country: Sales and Market Shares, 2010Table 4.2 Leading MS Markets: Revenue Forecasts by Country, 2010-2015Table 4.3 Leading MS Markets: Revenue Forecasts by Country, 2016-2022Table 4.4 US MS Drug Revenues, 2010-2022Table 4.5 German MS Drug Revenues, 2010-2022Table 4.6 French MS Drug Revenues, 2010-2022Table 4.7 Spanish MS Drug Revenues, 2010-2022Table 4.8 Italian MS Drug Revenues, 2010-2022Table 4.9 UK MS Drug Revenues, 2010-2022Table 4.10 Japanese MS Drug Revenues, 2010-2022Table 4.11 Indian MS Drug Revenues, 2010-2022Table 4.12 Chinese MS Drug Revenues, 2010-2022Table 5.1 Copaxone Revenues, 2010-2022Table 5.2 Avonex Revenues, 2010-2022Table 5.3 Rebif Revenues, 2010-2022Table 5.4 Betaseron/Betaferon Revenues, 2010-2022Table 5.5 Tysabri Revenues, 2010-2022Table 5.6 Extavia Revenues, 2010-2022Table 5.7 Gilenya Revenues, 2010-2022Table 6.1 MS Drugs and Their Producers, 2010Table 6.2 MS Drug Producers' Revenues, 2010Table 6.3 Biogen Idec Multiple Sclerosis Drug Pipeline, 2011Table 7.1 The Multiple Sclerosis Disease-Modifying Drug Pipeline, 2011Table 7.2 Preclinical Disease-Modifying Multiple Sclerosis Agents, 2011Table 8.1 SWOT Analysis of the MS Drug Industry and Market, 2011Table 8.2 Numbers of Medical MRI Scanners per 1,000,000 of Population for Leading MS Treatment Markets
List of Figures
Figure 3.1 Breakdown of the Multiple Sclerosis Market by Drug, 2010Figure 3.2 MS Drug Market Forecast, 2010-2022Figure 3.3 MS Drug Forecasts, 2010-2022Figure 3.4 MS Drug Revenues and Market Shares, 2022Figure 4.1 MS Drug Market Shares by Leading Country, 2010Figure 4.2 US MS Drug Revenues, 2010-2022Figure 4.3 German MS Drug Revenues, 2010-2022Figure 4.4 French MS Drug Revenues, 2010-2022Figure 4.5 Spanish MS Drug Revenues, 2010-2022Figure 4.6 Italian MS Drug Revenues, 2010-2022Figure 4.7 UK MS Drug Revenues, 2010-2022Figure 4.8 Japanese MS Drug Revenues, 2010-2022Figure 4.9 Indian MS Drug Revenues, 2010-2022Figure 4.10 Chinese MS Drug Revenues, 2010-2022Figure 5.1 Copaxone Revenues, 2010-2022Figure 5.2 Avonex Revenues, 2010-2022Figure 5.3 Rebif Revenues, 2010-2022Figure 5.4 Betaseron/Betaferon Revenues, 2010-2022Figure 5.5 Tysabri Revenues, 2010-2022Figure 5.6 Extavia Revenues, 2010-2022Figure 5.7 Gilenya Revenues, 2010-2022Figure 5.8 Gilenya Sales, Q4 2010-Q3 2011
Companies ListedAbbott Laboratories
Accentia
Acorda Therapeutics
Actelion
Active Biotech
Adeona
Advancell
Allozyne
Ambrx
Amplimmune
Apitope
Artielle Immunotherapeutics
Athersys
Axxam
Barofold
Baxter Healthcare Corporation
Bayer Schering
Bayhill Therapeutics
Biogen Idec
BioMS Medical Corp
Bionomics
Biopartners
Biotest
Biovista
BTG
Canbex Therapeutics
Celgene
Cell Therapeutics
CenTRion Therapeutics
Charite University
Chiron
Chromos Molecular Systems
CinnaGens
Clinical Data
Cognosci
Compugen
Daiichi Sankyo
Duke University
Elan Pharmaceuticals
European Medicines Agency (EMA)
Evotec
Fast Forward
FivePrime Therapeutics
Food and Drug Administration (FDA, US)
Genentech
GeNeuro
Genmab
Genzyme
GlaxoSmithKline (GSK)
Glenmark Pharmaceuticals
GTC Biotherapeutics
GW Pharmaceuticals
Hard to Treat Diseases (HTDS)
Hemispherx Biopharma
Henry Ford Health System
Hospices Civils de Lyon
Howard Florey Institute
Immune Tolerance Network
Innate Therapeutics
International Multiple Sclerosis Management Practice
Jewish General Hospital Lady David Institute
Kineta
Landsteiner
LTKFarma
McGill University
MediciNova
Merck KGaA
Merck Serono
Momenta Pharmaceuticals
Multiple Sclerosis Research Center of New York
Multiple Sclerosis Trust (UK)
Mylan
Natco Pharma
National Health Service (NHS, UK)
National Institute for Health and Clinical Excellence (NICE, UK)
National Institute of Allergy and Infectious Diseases
National Institute of Neurological Disorders and Strokes
National Institutes of Health Clinical Centre
National Multiple Sclerosis Society (US)
Neurotec Pharma
Northwestern University
Novartis
NovImmune
Nuron
Ono Pharmaceutical Co.
Opexa Therapeutics
Oregon Health & Science University
Peninsula College of Medicine and Dentistry, Clinical Neurology Research and Trials Group
Peptimmune
Pfizer
Pluristem Therapeutics
Prescription Solutions
Probiomed
ProtAffin
Provid Pharmaceuticals
Purdue University
Receptopharm
Receptos
RegeneRX
Roche
Rush University Medical Centre
Sandoz (part of Novartis)
Sanofi
Santen Pharmaceutical Co
ScreeningPort
Slavica Biochem
Stem Cell Network (Canada)
Stem Cell Therapeutics
SUNY Downstate Medical Centre
SuppreMol
Teva Pharmaceutical Industries
The Gladstone Institutes
Trophos
UC Boulder
United States National Multiple Sclerosis Society
University of Calgary
University of California Davis
University of California San Francisco
University of Louisville
University of Sao Paolo
Uppsala University
World Health Organization (WHO)
To order this report:Drug and Medication Industry: Multiple Sclerosis Treatment: World Drug Market 2012-2022More
Market Research ReportCheck our
Industry Analysis and InsightsNicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article